Low molecular weight heparin vs unfractionated heparin
Extracorporeal circuit thrombosis Median · adults with kidney failure treated with long‐term HD
1 finding from 1 review
- 1.58 [0.46, 5.42]3 studies · 91 participantsLow
Findings
What do systematic reviews say?
4,410 questions · 8,901 findings · 1,091 reviews
No studies found 1,687 · 19%GRADE not reported 1,469 · 16.5%Very low 1,969 · 22.1%Low 2,060 · 23.1%Moderate 1,302 · 14.6%High 414 · 4.7%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Low molecular weight heparin vs unfractionated heparin
Major bleeding · adults with kidney failure treated with long‐term HD
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs unfractionated heparin
Death (any cause) (median · adults with kidney failure treated with long‐term HD
Low molecular weight heparin showed no clear difference in death (any cause) Median compared with unfractionated heparin (low certainty).
1 finding from 1 review
- RR 2.64 [0.51, 13.83]3 studies · 120 participantsLow
Low molecular weight heparin vs unfractionated heparin
Dialysis vascular access thrombosis Median · adults with kidney failure treated with long‐term HD
Low molecular weight heparin showed no clear difference in dialysis vascular access thrombosis Median compared with unfractionated heparin (low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.7]2 studies · 45 participantsLow
Low molecular weight heparin vs unfractionated heparin
Dialysis vascular adequacy (Kt/V) · adults with kidney failure treated with long‐term HD
1 finding from 1 review
- no estimate extracted1 study · 20 participantsLow
Low molecular weight heparin vs unfractionated heparin
Minor bleeding · adults with kidney failure treated with long‐term HD
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs unfractionated heparin
Blood transfusion · adults with kidney failure treated with long‐term HD
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Low molecular weight heparin vs no prophylaxis
PE: assessed by CT arteriography ( · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in PE: assessed by CT arteriography ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes onlyRR 1.81 [0.49, 6.65]3 studies · 1820 participantsModerate
Low molecular weight heparin vs no prophylaxis
Symptomatic DVT · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).
1 finding from 1 review
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes onlyRR 0.61 [0.18, 2.03]4 studies · 1848 participantsLow
Low molecular weight heparin vs no prophylaxis
Asymptomatic DVT · adults undergoing KA
It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).
1 finding from 1 review
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes onlyRR 0.14 [0.03, 0.61]2 studies · 369 participantsVery low
Low molecular weight heparin vs no prophylaxis
All‐cause mortality ( · adults undergoing KA
1 finding from 1 review
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 1978 participantsGRADE not reported
Low molecular weight heparin vs no prophylaxis
All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).
1 finding from 1 review
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes onlyRR 1.85 [0.95, 3.59]5 studies · 1978 participantsModerate
Low molecular weight heparin vs no prophylaxis
Major bleeding · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes onlyRR 0.98 [0.06, 15.72]1 study · 1451 participantsModerate
Low molecular weight heparin vs no prophylaxis
Minor bleeding · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes onlyRR 1.79 [0.84, 3.84]5 studies · 1978 participantsModerate
Lower blood pressure targets vs standard blood pressure targets
Total mortality · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total mortality compared with standard blood pressure targets (moderate certainty).
1 finding from 1 review
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes onlyRR 1.05 [0.91, 1.23]7 studies · 9595 participantsModerate
Lower blood pressure targets vs standard blood pressure targets
Total serious adverse events · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
1 finding from 1 review
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes onlyRR 1.01 [0.94, 1.08]7 studies · 9595 participantsLow
Lower blood pressure targets vs standard blood pressure targets
Cardiovascular events · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total cardiovascular events compared with standard blood pressure targets (low certainty).
1 finding from 1 review
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes onlyRR 0.89 [0.8, 1]7 studies · 9595 participantsLow
Lower blood pressure targets vs standard blood pressure targets
Cardiovascular mortality · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in cardiovascular mortality compared with standard blood pressure targets (moderate certainty).
1 finding from 1 review
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes onlyRR 1.03 [0.82, 1.29]6 studies · 9484 participantsModerate
Lower blood pressure targets vs standard blood pressure targets
Withdrawals due to adverse events · cardiovascular disease with high blood pressure
It is very uncertain whether lower blood pressure targets changes participant withdrawals due to adverse effects compared with standard blood pressure targets (very low certainty).
1 finding from 1 review
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease 2022 · Cochrane Headline outcomes onlyRR 8.16 [2.06, 32.28]3 studies · 801 participantsVery low
Low molecular weight heparin vs unfractionated heparin
Outcomes · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found